688658 悦康药业
已收盘 04-27 15:00:01
资讯
新帖
简况
每周股票复盘:悦康药业(688658)募投项目变更用于新药研发
证券之星 · 04-26 06:31
每周股票复盘:悦康药业(688658)募投项目变更用于新药研发
4月22日悦康药业涨5.49%,富国医药创新股票A基金重仓该股
证券之星 · 04-22
4月22日悦康药业涨5.49%,富国医药创新股票A基金重仓该股
4月15日悦康药业涨8.59%,富国精准医疗混合A基金重仓该股
证券之星 · 04-15
4月15日悦康药业涨8.59%,富国精准医疗混合A基金重仓该股
悦康药业最新公告:子公司YKYY026注射液获临床试验批准
证券之星 · 04-13
悦康药业最新公告:子公司YKYY026注射液获临床试验批准
悦康药业(688658)披露子公司YKYY018雾化吸入剂获人偏肺病毒感染临床试验批准,4月3日股价下跌3.07%
证券之星 · 04-03
悦康药业(688658)披露子公司YKYY018雾化吸入剂获人偏肺病毒感染临床试验批准,4月3日股价下跌3.07%
悦康药业最新公告:创新药YKYY018雾化吸入剂获人偏肺病毒治疗与预防临床试验批准全球范围内尚未有获批上市的相关药物和疫苗
证券之星 · 04-02
悦康药业最新公告:创新药YKYY018雾化吸入剂获人偏肺病毒治疗与预防临床试验批准全球范围内尚未有获批上市的相关药物和疫苗
股市必读:悦康药业(688658)今年截至3月26日累计跌幅已超20%
证券之星 · 03-27
股市必读:悦康药业(688658)今年截至3月26日累计跌幅已超20%
三部门发文规范中医药服务管理;药监局助力器械临床创新成果转化
21世纪经济报道 · 03-25
三部门发文规范中医药服务管理;药监局助力器械临床创新成果转化
悦康药业(688658.SH):YKYY018雾化吸入剂治疗与预防人偏肺病毒感染的适应症获FDA临床试验批准
智通财经 · 03-24
悦康药业(688658.SH):YKYY018雾化吸入剂治疗与预防人偏肺病毒感染的适应症获FDA临床试验批准
股市必读:悦康药业年报 - 第四季度单季净利润同比下降33.02%
证券之星 · 03-23
股市必读:悦康药业年报 - 第四季度单季净利润同比下降33.02%
每周股票复盘:悦康药业(688658)2025年净亏损2.62亿元
证券之星 · 03-22
每周股票复盘:悦康药业(688658)2025年净亏损2.62亿元
悦康药业(688658.SH)发布2025年度业绩,由盈转亏2.62亿元
智通财经 · 03-20
悦康药业(688658.SH)发布2025年度业绩,由盈转亏2.62亿元
悦康药业(688658)披露控股股东部分股份司法拍卖流拍公告,3月17日股价上涨1.4%
证券之星 · 03-17
悦康药业(688658)披露控股股东部分股份司法拍卖流拍公告,3月17日股价上涨1.4%
3月6日悦康药业涨6.10%,富国精准医疗混合A基金重仓该股
中金财经 · 03-06
3月6日悦康药业涨6.10%,富国精准医疗混合A基金重仓该股
3月2日悦康药业跌8.26%,富国精准医疗混合A基金重仓该股
证券之星 · 03-02
3月2日悦康药业跌8.26%,富国精准医疗混合A基金重仓该股
方舟健客与悦康药业达成战略合作,以AI技术推动慢病服务数智升级
中金财经 · 02-28
方舟健客与悦康药业达成战略合作,以AI技术推动慢病服务数智升级
方舟健客与悦康药业达成战略合作 携手推进人工智能驱动的慢性病管理服务
美股速递 · 02-28
方舟健客与悦康药业达成战略合作 携手推进人工智能驱动的慢性病管理服务
悦康药业:控股股东持有的172万股公司股份将被司法拍卖
每日经济新闻 · 02-25
悦康药业:控股股东持有的172万股公司股份将被司法拍卖
悦康药业(688658)披露董事、高级管理人员离任暨补选职工董事公告,2月24日股价下跌0.43%
证券之星 · 02-24
悦康药业(688658)披露董事、高级管理人员离任暨补选职工董事公告,2月24日股价下跌0.43%
每周股票复盘:悦康药业(688658)董事及高管人事变动
证券之星 · 02-15
每周股票复盘:悦康药业(688658)董事及高管人事变动
加载更多
公司概况
公司名称:
悦康药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2020-12-24
主营业务:
悦康药业集团股份有限公司的主营业务是药品研发、生产制造、流通销售。公司的主要产品是银杏叶提取物注射液、奥美拉唑肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠(自产)、注射用头孢呋辛钠(明可欣)、活心丸(浓缩丸)。公司连续多年入选工信部医药工业百强,连续多年入选工信部中国医药研发产品线最佳工业企业。在2025年第42届全国医药工业信息年会上公司又一次强势入围,并荣获“2025年中国医药研发产品线工业企业优秀案例”荣誉;此外,公司荣获“2025中国药品研发综合实力百强”、“2025中国中药研发实力”第6位等荣誉。公司已获国家科技进步二等奖2项,承担省部级以上科技项目50余项,国家级重大专项23项,已获授权专利400余项,公司创新能力持续增强。
发行价格:
24.36
{"stockData":{"symbol":"688658","market":"SH","secType":"STK","nameCN":"悦康药业","latestPrice":19.47,"timestamp":1777273201000,"preClose":19.28,"halted":0,"volume":9400727,"delay":0,"changeRate":0.0099,"floatShares":450000000,"shares":450000000,"eps":-1.4412,"marketStatus":"已收盘","change":0.19,"latestTime":"04-27 15:00:01","open":19.28,"high":19.64,"low":18.7,"amount":180000000,"amplitude":0.0488,"askPrice":19.49,"askSize":12,"bidPrice":19.47,"bidSize":123,"shortable":0,"etf":0,"ttmEps":-1.4412,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777339800000},"marketStatusCode":5,"adr":0,"adjPreClose":19.28,"symbolType":"stock_kcb","openAndCloseTimeList":[[1777253400000,1777260600000],[1777266000000,1777273200000]],"highLimit":21.21,"lowLimit":17.35,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":450000000,"isCdr":false,"pbRate":2.64,"roa":"--","roe":"--","epsLYR":-0.59,"committee":-0.210169,"marketValue":8762000000,"turnoverRate":0.0209,"status":0,"afterMarket":{"amount":36272.61,"volume":1863,"close":19.47,"buyVolume":0,"sellVolume":237,"time":1777275237558,"indexStatus":"已收盘 04-27 15:30:00","preClose":19.28},"floatMarketCap":8762000000},"requestUrl":"/m/hq/s/688658","defaultTab":"news","newsList":[{"id":"2630807747","title":"每周股票复盘:悦康药业(688658)募投项目变更用于新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2630807747","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630807747?lang=zh_cn&edition=full","pubTime":"2026-04-26 06:31","pubTimestamp":1777156260,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,悦康药业报收于19.28元,较上周的19.93元下跌3.26%。本周,悦康药业4月23日盘中最高价报20.46元。悦康药业当前最新总市值86.76亿元,在化学制药板块市值排名64/150,在两市A股市值排名2273/5200。公司公告汇总悦康药业集团股份有限公司因部分募投项目变更及结项,将节余募集资金用于新增募投项目“小核酸药物及mRNA疫苗研发项目”及永久补充流动资金。专户仅用于特定募投项目募集资金的存放与使用,不得存放非募集资金或作其他用途。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600003947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629015184","title":"4月22日悦康药业涨5.49%,富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629015184","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629015184?lang=zh_cn&edition=full","pubTime":"2026-04-22 16:30","pubTimestamp":1776846615,"startTime":"0","endTime":"0","summary":"证券之星消息,4月22日悦康药业涨5.49%,收盘报19.8元,换手率3.02%,成交量13.59万手,成交额2.64亿元。重仓悦康药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为富国基金的富国医药创新股票A。富国医药创新股票A目前规模为9.48亿元,最新净值1.717,较上一交易日下跌1.05%,近一年上涨33.73%。该公募基金现任基金经理为赵伟 王超。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200037757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09939","688658","159938","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627404205","title":"4月15日悦康药业涨8.59%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627404205","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627404205?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:10","pubTimestamp":1776240613,"startTime":"0","endTime":"0","summary":"证券之星消息,4月15日悦康药业涨8.59%,收盘报20.61元,换手率5.08%,成交量22.85万手,成交额4.56亿元。重仓悦康药业的前十大公募基金请见下表:根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共24家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元,最新净值3.225,较上一交易日下跌0.52%,近一年上涨17.57%。该公募基金现任基金经理为赵伟。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500028544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627439462","title":"悦康药业最新公告:子公司YKYY026注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2627439462","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627439462?lang=zh_cn&edition=full","pubTime":"2026-04-13 17:49","pubTimestamp":1776073771,"startTime":"0","endTime":"0","summary":"悦康药业公告称,公司子公司北京悦康科创、杭州天龙近日获得国家药监局核准签发的关于YKYY026注射液的《药物临床试验批准通知书》。该药品为编码水痘-带状疱疹病毒gE蛋白抗原的mRNA疫苗,用于预防带状疱疹,同意在≥40岁人群中开展I期临床试验。YKYY026注射液采用自主知识产权的突变位点组合及LNP递送系统,此前已获得美国FDA临床试验批准。公司将积极推进研发及注册进度,并及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300024084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624659781","title":"悦康药业(688658)披露子公司YKYY018雾化吸入剂获人偏肺病毒感染临床试验批准,4月3日股价下跌3.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624659781","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624659781?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:52","pubTimestamp":1775209935,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,悦康药业报收于19.29元,较前一交易日下跌3.07%,最新总市值为86.8亿元。悦康药业集团股份有限公司全资子公司北京悦康科创医药科技股份有限公司近日获得国家药品监督管理局关于YKYY018雾化吸入剂用于治疗与预防人偏肺病毒感染的两份《药物临床试验批准通知书》。此前该产品已获NMPA和FDA批准开展针对呼吸道合胞病毒感染的临床试验。目前全球尚无获批的人偏肺病毒感染治疗药物或疫苗,临床需求迫切。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624577141","title":"悦康药业最新公告:创新药YKYY018雾化吸入剂获人偏肺病毒治疗与预防临床试验批准全球范围内尚未有获批上市的相关药物和疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2624577141","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624577141?lang=zh_cn&edition=full","pubTime":"2026-04-02 17:50","pubTimestamp":1775123412,"startTime":"0","endTime":"0","summary":"悦康药业公告称,公司全资子公司悦康科创近日获得国家药品监督管理局关于同意YKYY018雾化吸入剂用于人偏肺病毒治疗与预防的两份《药物临床试验批准通知书》。截至目前,全球范围内尚未有获批上市的人偏肺病毒感染治疗药物和疫苗,临床治疗和预防领域存在显著且迫切的未被满足需求。该产品近日也已获得FDA核准签发的关于YKYY018雾化吸入剂用于预防和治疗人偏肺病毒感染进行临床试验的函告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200032595.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK1161","159646","159992","BK1574","06978","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622458893","title":"股市必读:悦康药业(688658)今年截至3月26日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622458893","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622458893?lang=zh_cn&edition=full","pubTime":"2026-03-27 02:49","pubTimestamp":1774550947,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘,悦康药业报收于17.1元,下跌0.29%,换手率1.42%,成交量6.37万手,成交额1.1亿元。当日关注点来自交易信息汇总:悦康药业3月26日收盘报17.1元,跌0.29%,当日成交637.31万元,年内累计跌幅达22.04%。前10个交易日资金流向情况:主力资金累计净流出653.27万元,股价累计下跌5.73%;融资余额累计减少104.78万元,融券余量累计增加7026股。该股最近90天内共有1家机构给出评级,买入评级1家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700004515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622043217","title":"三部门发文规范中医药服务管理;药监局助力器械临床创新成果转化","url":"https://stock-news.laohu8.com/highlight/detail?id=2622043217","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622043217?lang=zh_cn&edition=full","pubTime":"2026-03-25 10:06","pubTimestamp":1774404374,"startTime":"0","endTime":"0","summary":"政策动向三部门发文规范基层医疗卫生机构中医药服务管理3月24日,国家中医药局、国家卫生健康委、国家疾控局联合发布《乡镇卫生院社区卫生服务中心中医药服务管理基本规范》,明确乡镇卫生院、社区卫生服务中心应能提供中药饮片、针刺、艾灸、刮痧砭术、拔罐、中医微创、推拿、敷熨熏浴、骨伤、肛肠等项目中的6类10项以上中医药技术方法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603253683741047.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253683741047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TLX","688658","BK0239","300006","BK4139","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621054379","title":"悦康药业(688658.SH):YKYY018雾化吸入剂治疗与预防人偏肺病毒感染的适应症获FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2621054379","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621054379?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:46","pubTimestamp":1774338399,"startTime":"0","endTime":"0","summary":"智通财经APP讯,悦康药业(688658.SH)公告,公司全资子公司北京悦康科创医药科技股份有限公司(简称“悦康科创”)于近日获得美国食品药品监督管理局(简称“FDA”)关于同意YKYY018雾化吸入剂用于人偏肺病毒治疗与预防的临床试验申请的函告。公告显示,YKYY018雾化吸入剂是公司依托全流程AI平台自主开发的一款国际原创的膜融合抑制剂药物。YKYY018项目针对呼吸道合胞病毒(RSV)感染的临床Ⅰ期研究正在稳步推进中,本次获批人偏肺病毒治疗与预防适应症,标志着该管线布局从单一病毒向重要呼吸道病毒谱全面拓展,为婴幼儿、老年人等高风险人群提供更全面的防治选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","688658","BK0239","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621467307","title":"股市必读:悦康药业年报 - 第四季度单季净利润同比下降33.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621467307","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621467307?lang=zh_cn&edition=full","pubTime":"2026-03-23 03:32","pubTimestamp":1774207937,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘,悦康药业报收于17.9元,下跌2.45%,换手率1.25%,成交量5.64万手,成交额1.03亿元。来自:悦康药业2025年归母净利润亏损2.62亿元,同比下降312.09%。股本股东变化股东户数变动近日悦康药业披露,截至2026年2月28日公司股东户数为1.3万户,较12月31日增加3327.0户,增幅为34.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300001409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621606799","title":"每周股票复盘:悦康药业(688658)2025年净亏损2.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621606799","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621606799?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:57","pubTimestamp":1774119428,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘,悦康药业报收于17.9元,较上周的17.98元下跌0.44%。本周,悦康药业3月17日盘中最高价报19.7元。悦康药业当前最新总市值80.55亿元,在化学制药板块市值排名64/150,在两市A股市值排名2332/5190。本周关注点来自业绩披露要点:悦康药业2025年归母净利润为-2.62亿元,同比下降312.09%。股本股东变化截至2026年2月28日,悦康药业股东户数为1.3万户,较2025年12月31日增加3327户,增幅达34.33%。2025年度营业收入扣除与主业无关收入629.98万元,占比0.26%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620573918","title":"悦康药业(688658.SH)发布2025年度业绩,由盈转亏2.62亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620573918","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620573918?lang=zh_cn&edition=full","pubTime":"2026-03-20 21:07","pubTimestamp":1774012026,"startTime":"0","endTime":"0","summary":"智通财经APP讯,悦康药业 发布2025年年度报告,报告期内,公司实现营业收入24.46亿元,同比下降35.30%。归属于上市公司股东的净亏损2.62亿元。基本每股亏损0.59元。报告期内,公司继续保持高比例研发投入,研发费用同比上升,高比例的研发投入对公司净利润产生了一定影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"悦康药业(688658.SH)发布2025年度业绩,由盈转亏2.62亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620440387","title":"悦康药业(688658)披露控股股东部分股份司法拍卖流拍公告,3月17日股价上涨1.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620440387","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620440387?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:10","pubTimestamp":1773738655,"startTime":"0","endTime":"0","summary":"截至2026年3月17日收盘,悦康药业报收于18.88元,较前一交易日上涨1.4%,最新总市值为84.96亿元。该股当日开盘18.63元,最高19.7元,最低18.5元,成交额达2.5亿元,换手率为2.9%。近日,悦康药业集团股份有限公司发布《关于控股股东所持公司部分股份被司法拍卖流拍的公告》。公告显示,控股股东阜阳京悦永顺信息咨询有限公司持有的公司1,720,000股无限售流通股股票因在规定时间内无人出价已流拍。公司将继续关注后续进展并履行信息披露义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700029337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617683137","title":"3月6日悦康药业涨6.10%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2617683137","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617683137?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:34","pubTimestamp":1772786054,"startTime":"0","endTime":"0","summary":"证券之星消息,3月6日悦康药业涨6.10%,收盘报18.96元,换手率2.51%,成交量11.29万手,成交额2.11亿元。重仓悦康药业的前十大公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共23家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元,最新净值2.7836,较上一交易日上涨2.09%,近一年上涨15.59%。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202603/06/20260306552441.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202603/06/20260306552441.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260306/32049950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616038489","title":"3月2日悦康药业跌8.26%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616038489","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616038489?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:34","pubTimestamp":1772440448,"startTime":"0","endTime":"0","summary":"证券之星消息,3月2日悦康药业跌8.26%创60日新低,收盘报18.88元,换手率3.46%,成交量15.59万手,成交额3.0亿元。重仓悦康药业的前十大公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共23家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.77亿元,最新净值2.9119,较上一交易日上涨0.38%,近一年上涨20.31%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200022785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614818455","title":"方舟健客与悦康药业达成战略合作,以AI技术推动慢病服务数智升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2614818455","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614818455?lang=zh_cn&edition=full","pubTime":"2026-02-28 15:40","pubTimestamp":1772264414,"startTime":"0","endTime":"0","summary":"2月28日,方舟健客与悦康药业集团在北京成功举行战略合作签约仪式。悦康药业集团董事于鹏飞表示,此次与方舟健客的战略合作,是企业从“药品供给”向“健康服务”延伸的重要布局。方舟健客与悦康药业达成战略合作,不仅是“AI技术+慢病服务+创新医药+产业链供给”四大优势的深度融合,更是双方积极响应国家健康战略、破解行业痛点的共同责任担当。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202602/28/20260228127987.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202602/28/20260228127987.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260228/32034846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688658","06086","BK1247","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175060632","title":"方舟健客与悦康药业达成战略合作 携手推进人工智能驱动的慢性病管理服务","url":"https://stock-news.laohu8.com/highlight/detail?id=1175060632","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175060632?lang=zh_cn&edition=full","pubTime":"2026-02-28 15:14","pubTimestamp":1772262851,"startTime":"0","endTime":"0","summary":"方舟健客与悦康药业集团宣布建立战略联盟,共同致力于利用人工智能技术推动慢性病管理服务的创新与发展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","06086","688658","BK1247"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614708066","title":"悦康药业:控股股东持有的172万股公司股份将被司法拍卖","url":"https://stock-news.laohu8.com/highlight/detail?id=2614708066","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614708066?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:20","pubTimestamp":1772025600,"startTime":"0","endTime":"0","summary":"每经AI快讯,2月25日,悦康药业公告,控股股东阜阳京悦永顺信息咨询有限公司持有的本公司172万股无限售流通股股票将被司法拍卖。该事项不会影响公司控制权稳定,亦不会对公司日常经营管理造成影响。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-02-25/doc-inhnzvzk2137962.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-25/doc-inhnzvzk2137962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613040792","title":"悦康药业(688658)披露董事、高级管理人员离任暨补选职工董事公告,2月24日股价下跌0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613040792","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613040792?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:26","pubTimestamp":1771928776,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘,悦康药业报收于21.0元,较前一交易日下跌0.43%,最新总市值为94.5亿元。悦康药业集团股份有限公司近日发布《关于公司董事、高级管理人员离任暨补选职工董事的公告》。公告显示,公司董事会于近日收到职工代表董事张伟先生、副总经理杨磊先生的书面辞任报告。杨磊先生已当选为公司第三届董事会职工代表董事,任期自2026年2月13日起至本届董事会任期届满。上述人员变动不影响公司董事会正常运作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400037363.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611145858","title":"每周股票复盘:悦康药业(688658)董事及高管人事变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2611145858","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611145858?lang=zh_cn&edition=full","pubTime":"2026-02-15 01:48","pubTimestamp":1771091292,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘,悦康药业报收于21.09元,较上周的22.2元下跌5.0%。本周,悦康药业2月10日盘中最高价报23.6元。公司公告汇总悦康药业集团股份有限公司董事会于近日收到职工代表董事张伟先生、副总经理杨磊先生的书面辞任报告。杨磊先生已当选为公司第三届董事会职工代表董事,任期自2026年2月13日起至本届董事会任期届满。上述人员变动不影响公司董事会正常运作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688658","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777337890519,"stockEarnings":[{"period":"1week","weight":-0.0026},{"period":"1month","weight":0.1031},{"period":"3month","weight":-0.2552},{"period":"6month","weight":-0.0621},{"period":"1year","weight":0.134},{"period":"ytd","weight":-0.1389}],"compareEarnings":[{"period":"1week","weight":0.001},{"period":"1month","weight":0.0441},{"period":"3month","weight":-0.0129},{"period":"6month","weight":0.0174},{"period":"1year","weight":0.2401},{"period":"ytd","weight":0.0296}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"悦康药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13019人(较上一季度增加34.33%)","perCapita":"34564股","listingDate":"2020-12-24","address":"北京市大兴区北京经济技术开发区宏达中路6号","registeredCapital":"45000万元","survey":" 悦康药业集团股份有限公司的主营业务是药品研发、生产制造、流通销售。公司的主要产品是银杏叶提取物注射液、奥美拉唑肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠(自产)、注射用头孢呋辛钠(明可欣)、活心丸(浓缩丸)。公司连续多年入选工信部医药工业百强,连续多年入选工信部中国医药研发产品线最佳工业企业。在2025年第42届全国医药工业信息年会上公司又一次强势入围,并荣获“2025年中国医药研发产品线工业企业优秀案例”荣誉;此外,公司荣获“2025中国药品研发综合实力百强”、“2025中国中药研发实力”第6位等荣誉。公司已获国家科技进步二等奖2项,承担省部级以上科技项目50余项,国家级重大专项23项,已获授权专利400余项,公司创新能力持续增强。","listedPrice":24.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"悦康药业(688658)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供悦康药业(688658)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"悦康药业,688658,悦康药业股票,悦康药业股票老虎,悦康药业股票老虎国际,悦康药业行情,悦康药业股票行情,悦康药业股价,悦康药业股市,悦康药业股票价格,悦康药业股票交易,悦康药业股票购买,悦康药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"悦康药业(688658)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供悦康药业(688658)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}